Close Menu

NEW YORK – Swiss startup 4D Lifetec and epigenetic diagnostic firm VolitionRx said Tuesday that they have partnered to evaluate whether combining their respective assay technologies can better identify individuals with early-stage cancer.

Under the agreement the companies intend to conduct a clinical validation trial using their platforms in a set of lung cancer clinical samples.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.